Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 27465-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- HMGB3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated HMGB3 antibody (Cat. #27465-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway.
Loss of exosomal micro-RNA-200b-3p from hypoxia cancer-associated fibroblasts reduces sensitivity to 5-flourouracil in colorectal cancer through targeting high-mobility group box 3.
HMGB3 is a Potential Therapeutic Target by Affecting the Migration and Proliferation of Colorectal Cancer.
Overexpression of MiR-633 Suppresses the Tumorigenicity of Gastric Cancer Cells and Induces Apoptosis by Targeting MAPK1.
Circular RNA 0001313 Knockdown Suppresses Non-Small Cell Lung Cancer Cell Proliferation and Invasion via the microRNA-452/HMGB3/ERK/MAPK Axis.
Targeting HMGB3/hTERT axis for radioresistance in cervical cancer.
Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus.
Ma H, Qi G, Han F, Gai P, Peng J, Kong B
Cell communication and signaling : CCS 2023 Jun 16;21(1):144
Cell communication and signaling : CCS 2023 Jun 16;21(1):144
Loss of exosomal micro-RNA-200b-3p from hypoxia cancer-associated fibroblasts reduces sensitivity to 5-flourouracil in colorectal cancer through targeting high-mobility group box 3.
Yuan H, Chen B, Chai R, Gong W, Wan Z, Zheng B, Hu X, Guo Y, Gao S, Dai Q, Yu P, Tu S
Frontiers in oncology 2022;12:920131
Frontiers in oncology 2022;12:920131
HMGB3 is a Potential Therapeutic Target by Affecting the Migration and Proliferation of Colorectal Cancer.
Gong W, Guo Y, Yuan H, Hu X, Chai R, Zheng B, Wan Z, Tu S
Frontiers in cell and developmental biology 2022;10:891482
Frontiers in cell and developmental biology 2022;10:891482
Overexpression of MiR-633 Suppresses the Tumorigenicity of Gastric Cancer Cells and Induces Apoptosis by Targeting MAPK1.
Li HL, Song YH, Du ZP, Hu YH, Wang ZX, Chen X, Lu XM, Chen YX, Duan YQ, Zhu XD
Current medical science 2022 Oct;42(5):1033-1045
Current medical science 2022 Oct;42(5):1033-1045
Circular RNA 0001313 Knockdown Suppresses Non-Small Cell Lung Cancer Cell Proliferation and Invasion via the microRNA-452/HMGB3/ERK/MAPK Axis.
Zhang S, Liu J, Yuan T, Liu H, Wan C, Le Y
International journal of general medicine 2020;13:1495-1507
International journal of general medicine 2020;13:1495-1507
Targeting HMGB3/hTERT axis for radioresistance in cervical cancer.
Li Z, Zhang Y, Sui S, Hua Y, Zhao A, Tian X, Wang R, Guo W, Yu W, Zou K, Deng W, He L, Zou L
Journal of experimental & clinical cancer research : CR 2020 Nov 13;39(1):243
Journal of experimental & clinical cancer research : CR 2020 Nov 13;39(1):243
Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus.
Zou M, Zhang X, Jiang D, Zhao Y, Wu T, Gong Q, Su H, Wu D, Moreland L, Li G
Genes 2020 Dec 21;11(12)
Genes 2020 Dec 21;11(12)
No comments: Submit comment
No validations: Submit validation data